Successful results from an Alzheimer’s disease study drove shares of Cassava Sciences (NASDAQ: SAVA) more than 400% higher last week. Then shareholders watched in horror as the biotech stock gave most of those gains back before the end of the week.
Is now the time to sell this biotech stock, or is the reversal a chance to buy more shares at a discount? To find out, let’s look at what’s next for Cassava Sciences and its Alzheimer’s disease candidate.
Alzheimer’s disease affects one in 10 Americans over the age of 65, and there aren’t any treatments approved to prevent this progressive disease from worsening. Pent-up demand for an effective Alzheimer’s disease treatment could make Cassava Sciences lead candidate, simufilam, the most successful new drug of its time.